佩米替尼Pemigatinib 4.5mg

For adult patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) fusions or other rearrangements. For adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangements.

Cholangiocarcinoma: The recommended dose is 13.5 mg orally once daily for 14 consecutive days, followed by a 7-day treatment-free interval, with a 21-day period as one cycle. Continue treatment until disease progression or unacceptable toxicity occurs. Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangements: The recommended dose is 13.5 mg orally once daily. Continue treatment until disease progression or unacceptable toxicity occurs. Patients with Severe Renal Impairment or Severe Hepatic Impairment: The recommended dose is 9 mg orally once daily. This product may be administered with or without food. Swallow the tablets whole; do not split or crush them.

Ocular Toxicity: This product may cause retinal pigment epithelial detachment. Hyperphosphatemia and Soft Tissue Mineralization: Monitor serum phosphorus levels and signs of soft tissue mineralization during treatment. Embryo-Fetal Toxicity: Administration to pregnant women may cause fetal harm.

Hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dry eye, serous retinal detachment, xeroderma, decreased appetite, etc.

14 tablets per box.

Store in a sealed container at a temperature between 20℃ and 25℃, with excursions permitted between 15℃ and 30℃.